

BioVitos Ltd. Completes FEMININ™ Clinical Study with 98.7% Participant Completion Rate

79 of 80 participants completed the full study – no discontinuations due to adverse events

LONDON, UK / STOCKHOLM, SWEDEN — 30 September 2026 — BioVitos Ltd. today announces the completion of its FEMININ™ clinical study, involving a total of 80 participants.

A total of 79 out of 80 participants completed the full study, representing a completion rate of 98.7%. The only participant who did not complete the study discontinued due to relocation, and not because of adverse events or any other treatment-related reason. Consequently, no participant discontinued the study due to adverse events.

Professor Fredrik Nyström, who leads the FEMININ™ study, considers the very high completion rate to be very positive from a tolerability perspective.

“When evaluating a clinical study from a tolerability perspective, participant completion is an important consideration. The exceptionally high completion rate in FEMININ is therefore a very positive observation. The full clinical data will now need to be analysed before any conclusions regarding the study can be presented.”

— Professor Fredrik Nyström, Principal Investigator, FEMININ™ study

“We are extremely pleased to have reached this important milestone. Having 79 out of 80 participants complete the study is a very strong operational result. We will now allow the scientific process to take its course and await the full analysis of the data before communicating any conclusions regarding the results.”

— Cato Crogh, Chairman of the Board, BioVitos Ltd.

All participants have now, as agreed, received SEK 2,000 in participant compensation. This was the compensation level specified for the study and approved as part of the ethical review process.

In accordance with scientific and clinical standards, BioVitos is not communicating any conclusions regarding the study's efficacy, safety or other clinical outcomes at this stage. The study data will now be analysed, and the results will be presented in connection with the subsequent scientific publication.

E N D S



About BioVitos Ltd.

BioVitos Ltd. is a life sciences company focused on research and development within iron deficiency and related health conditions.

The company's research activities include the FEMININ™ study and the development of its patented oral iron succinate technology, including SUCCIFER®.

BioVitos' objective is to develop accessible oral solutions for iron deficiency supported by clinical research and scientific evidence.

Media & Investor Contact

Cato Crogh, Chairman of the Board

Phone: +46 736 98 20 30

Email: cato@payzinos.com

BioVitos Ltd., c/o Bareham & Co

25 Cabot Square, London E14 4QZ, UK

info@biovitos.com · www.biovitos.com